Google
Trusted Resources: News & Events
Latest announcements and gatherings
Sickle Cell Disease Research Shows Progress in Preventing Related Complications and Death
Studies aim to limit pain crises, prevent strokes in kids, and save the lives of pregnant women with SCD.
Sickle cell disease (SCD) is an inherited chronic disorder characterized by rigid, sickle-shaped red blood cells that get stuck in veins and block blood flow, which can cause severe pain, stroke, organ failure, and complications leading to death. Each year, approximately 300,000 people around the world are born with SCD, and most of them lack access to comprehensive care or effective treatment options. In fact, the only established long-term therapy for SCD, a pill called hydroxyurea approved more than a decade ago to treat complications stemming from the disease, is widely underused in resource-poor countries.
There is an enormous need to improve the quality of life for people with SCD and decrease global mortality rates. Three studies presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego report on encouraging advances for SCD treatment that carry global public health implications.
+myBinderRelated Content
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
-
These patients had sickle-cell disease. Experimental therapies might have cured themScientists have long known what causes s...
-
Using CRISPR Cas9 to cure sickle cell diseasehttps://www.youtube.com/watch?v=WdkP-RU5...
-
L-Glutamine for sickle cell anemia: More questions than answersIn 2017, the Food and Drug Administratio...
-
Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled studyPURPOSE: Previous clinical trials sugges...
-
The Family Perspectivehttp://www.sicklecelltransplantconsortiu...
-
Investigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical TrialImara’s investigational oral inhibitor...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.